TrialJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer2018

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

A Lisberg et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.